FAAH

Fatty Acid Amide Hydrolase (FAAH) is an essential enzyme in the endocannabinoid system, responsible for breaking down bioactive fatty acid amides like anandamide (AEA) and regulating pain, inflammation, mood, and addiction pathways.

 Variations in the FAAH gene, particularly the C385A (P129T) polymorphism, influence enzyme stability and endocannabinoid tone, with clinical implications for pain sensitivity, addiction risk, and psychiatric conditions.

What is FAAH?

The Fatty Acid Amide Hydrolase (FAAH) gene encodes an enzyme that regulates endocannabinoid signaling by breaking down bioactive fatty acid amides like anandamide (AEA). 

FAAH modulates pain, inflammation, and mood by controlling endocannabinoid tone, mainly through the CB1 receptor. 

The FAAH gene, located on chromosome 1p33, encodes this enzyme. Its expression is enriched in the brain and liver and also in peripheral tissues.

Function of FAAH in the Human Body

FAAH is a key regulator of the endocannabinoid system (ECS), influencing neurological and physiological processes such as:

• Pain modulation – FAAH limits anandamide levels, affecting pain perception.
• Inflammatory control – FAAH regulates inflammatory pathways by modulating endocannabinoid signaling, influencing immune-related gene expression, WNT pathway activity, and chemokine receptor expression, which collectively may impact inflammation and wound healing.
• Mood and stress regulation – Anandamide degradation by FAAH affects anxiety, depression, and emotional resilience.
• Addiction and reward pathways – FAAH influences dopamine and opioid signaling, affecting addiction vulnerability.

Why is FAAH Important as a Biomarker?

FAAH’s activity has clinical significance in various conditions, including:

• Chronic pain syndromes – Altered FAAH function affects pain sensitivity and opioid responses.
• Anxiety and PTSD – Individuals with FAAH variations may have enhanced fear extinction and altered stress responses.
• Addiction risk – FAAH genetic variations influence susceptibility to substance use disorders.
• Neurodegenerative and inflammatory diseases – FAAH dysregulation is linked to Alzheimer’s, MS, and autoimmune conditions.

FAAH C385A Polymorphism (rs324420) and Clinical Impact

A common genetic variant (C385A; rs324420) leads to a proline-to-threonine (P129T) substitution, reducing FAAH enzyme stability. This results in higher anandamide levels, impacting:

• Fear extinction learning (enhanced in A-allele carriers).
• Reduced anxiety and stress responses.
• Altered pain perception and potentially increased resilience to chronic pain.
• Potentially increased addiction risk (especially in homozygous A/A individuals).

Who Should Get FAAH Tested?

FAAH genetic and functional testing may be helpful in:

• Patients with chronic pain who are unresponsive to conventional therapies.
• Individuals with PTSD or treatment-resistant anxiety disorders.
• Patients being considered for cannabinoid-based therapies.
• Those with unexplained high or low pain sensitivity.
• Individuals with a personal or family history of addiction, alcohol abuse, or neuroinflammatory conditions.

Situational Recommendations for FAAH Testing

• Pharmacogenomic testing – To assess response to FAAH inhibitors (e.g., PF-04457845) and cannabinoid-based treatments.
• Personalized psychiatry and pain management – Identifying individuals who may benefit from targeted anxiolytic or analgesic therapies.
• Research and clinical trials – FAAH testing is increasingly used in neurology, addiction medicine, and pain management studies.

Test Procedure and Interpretation

Testing for FAAH is often performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for FAAH genetic testing are considered to be without mutations that can alter the activity of the FAAH proteins.

Clinical Implications of Positive FAAH Mutations

The clinical implications of a positive FAAH mutation test result will vary by individual, although FAAH mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of various symptoms affecting mood, pain regulation, addiction behavior, anxiety, PTSD, or other conditions.

Patients or practitioners with questions about the clinical implications of FAAH mutations should seek further assessment with a genetic counselor or expert. 

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.